Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11808449 | 0.81 | ALDH1A1 (0.36) | PKMTDP1MAPK1ALDH1A1KDM4E | |
| SCHEMBL7632252 | 0.80 | — | — | |
| SCHEMBL8938593 | 0.73 | ALDH1A1 (0.46) | CA1CA2CA7CA9CA12 | |
| SCHEMBL2248550 | 0.72 | CA2 (0.43) | CA1CA2CA7CA9CA12 | |
| SCHEMBL10300057 | 0.72 | APP (0.77) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4082593 | 0.72 | CA1 (0.65) | CA1CA2CA7CA9CA12 | |
| SCHEMBL674764 | 0.72 | APP (0.77) | CA1CA2CA7CA9CA12 | |
| 1,4-Dimethoxybenzene SCHEMBL8489 | 0.71 | CA1 (1.00) | CA1CA2CA7CA9CA12 | |
| 1,4-Dimethoxybenzene SCHEMBL21802643 | 0.71 | CA1 (1.00) | CA1CA2CA7CA9CA12 | |
| SCHEMBL9715639 | 0.70 | APP (0.74) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265620-B1 | SPIRO DERIVATIVES OF PARTHENIN AS NOVEL ANTICANCER AGENTS | COUNCIL SCIENT IND RES (IN) | 2014-06-18 | — | — | EP | disclosed |
| US-8609858-B2 | Spiro derivatives of parthenin as novel anticancer agents | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-12-17 | — | — | US | disclosed |
| US-20110201661-A1 | Spiro Derivatives of Parthenin as Novel Anticancer Agents | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2011-08-18 | — | — | US | disclosed |
| EP-2265620-A1 | SPIRO DERIVATIVES OF PARTHENIN AS NOVEL ANTICANCER AGENTS | Council Of Scientific & Industrial Research (IN) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009110007-A1 | SPIRO DERIVATIVES OF PARTHENIN AS NOVEL ANTICANCER AGENTS | COUNCIL QF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201661-A1 | Spiro Derivatives of Parthenin as Novel Anticancer Agents | CDK10, NEK10, AKR1B10 | CA1 4049/4885CA2 3317/4885CA7 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.